T7781

Reynoutrin (Reinutrin) with antioxidant and radical-scavenging activity.

XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.

FAK-IN-14 is a highly effective focal adhesion kinase (FAK) inhibitor that induces apoptosis and cell cycle arrest. FAK-IN-14 has weak inhibitory effects on Akt, c-kit, MEK1/2 and mTOR, but has significant inhibitory effects on FAK, FGFR1 and Pyk2.

FAK-IN-15 is a highly potent focal adhesion kinase (FAK) inhibitor with antitumor activity.

SG3199-Val-Ala-PAB is an intermediate in the synthesis of Tesirine, a conjugate of agent-linker for antibody-drug conjugates (ADCs) used in cancer research [1].

Tomaymycin DM, a derivative of Tomaymycin, functions as a DNA alkylator and PBD dimer. It is utilized to formulate antibody-drug conjugates (ADCs) by attaching to tumor-targeting antibodies.

EC1167 hydrochloride serves as the linker for EC1169, a prostate-specific membrane antigen-targeting tubulysin conjugate. EC1169 hydrochloride demonstrates potential in treating recurrent metastatic, castration-resistant prostate cancer (MCRPC) [1].

Deruxtecan Analog 2 (example 9 P3), a Deruxtecan derivative, serves as an agent-linker conjugate integrating Camptothecin (CPT), a Topo I inhibitor active against colorectal, breast, lung, and ovarian cancers, with a distinct linker. This analog is employed in synthesizing anti-FGFR2 ADC [1].

Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 is a cleavable linker for antibody-drug conjugate (ADC) synthesis, enabling the attachment of therapeutic agents to antibodies [1].

Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) [1].

Fmoc-aminooxy-PEG2-NH2 is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs), aiding the targeted delivery of therapeutic agents [1].